{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T10:26:47Z","timestamp":1793183207869,"version":"4.5.0"},"reference-count":41,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T00:00:00Z","timestamp":1738108800000},"content-version":"vor","delay-in-days":28,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Infectious Diseases and Medical Microbiology"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:p>\n                    <jats:bold>Purpose:<\/jats:bold>\n                    To evaluate the pharmacology, pharmacokinetics, pharmacodynamics, antimicrobial activity, efficacy, safety, and the regulatory status of sulbactam\u2013durlobactam.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Summary:<\/jats:bold>\n                    Sulbactam\u2013durlobactam is a recently approved antimicrobial combination of two\n                    <jats:italic>\u03b2<\/jats:italic>\n                    \u2010lactamase inhibitors for the treatment of hospital\u2010acquired bacterial pneumonia (HABP) and ventilator\u2010associated bacterial pneumonia (VABP) associated with\n                    <jats:italic>Acinetobacter baumannii<\/jats:italic>\n                    \u2013calcoaceticus complex (ABC) in patients 18\u2009years and older. Sulbactam is a direct antibacterial activity with high susceptibility to\n                    <jats:italic>A. baumannii<\/jats:italic>\n                    species. Durlobactam, diazabicyclooctane\n                    <jats:italic>\u03b2<\/jats:italic>\n                    \u2010lactamase inhibitors possesses a broad\u2010spectrum activity against Ambler class A, C, and D serine\n                    <jats:italic>\u03b2<\/jats:italic>\n                    \u2010lactamases. This combination has been studied to overcome resistance to ABC species. Data were obtained from in vitro and preclinical studies as well as phase I, II, and III clinical studies published in English between 200t0 and January 2023. A phase II trial showed similar tolerability and pharmacokinetics parameters of sulbactam\u2013durlobactam in patients with urinary tract infections to placebo. However, no ABC infections were included in the trial. ATTACK, a phase III clinical trial of sulbactam\u2013durlobactam, studied the safety and efficacy of sulbactam\u2013durlobactam in patients with ABC HABP\/VABP and showed its noninferiority to colistin. Reported adverse events include anemia, elevated liver enzymes, hyperkalemia, headache, diarrhea, nausea, urticaria, and vascular pain. Sulbactam\u2013durlobactam is a new\n                    <jats:italic>\u03b2<\/jats:italic>\n                    \u2010lactamase inhibitors combination active against MDR Gram\u2010negative bacteria including ABC. It is currently approved for the treatment of HABP\/VABP caused by susceptible ABC strains.\n                  <\/jats:p>","DOI":"10.1155\/cjid\/2001136","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T06:06:09Z","timestamp":1738130769000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Sulbactam\u2013Durlobactam: A Novel Antibiotic Combination for the Treatment of\n                    <i>Acinetobacter baumannii<\/i>\n                    \u2013Calcoaceticus Complex (ABC) Hospital\u2010Acquired Bacterial Pneumonia and Ventilator\u2010Associated Bacterial Pneumonia"],"prefix":"10.1155","volume":"2025","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7310-9192","authenticated-orcid":false,"given":"Wissam K.","family":"Kabbara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elina","family":"Sadek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6383-0288","authenticated-orcid":false,"given":"Hanine","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,1,29]]},"reference":[{"key":"e_1_2_11_1_2","first-page":"767","article-title":"Recommendations From the 2016 Guidelines for the Management of Adults With Hospital-Acquired or Ventilator-Associated Pneumonia","volume":"42","author":"Kumar S. T.","year":"2017","journal-title":"P and T"},{"key":"e_1_2_11_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw504"},{"key":"e_1_2_11_3_2","doi-asserted-by":"publisher","DOI":"10.1513\/annalsats.201608-641cme"},{"key":"e_1_2_11_4_2","doi-asserted-by":"publisher","DOI":"10.1086\/668770"},{"key":"e_1_2_11_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04808-14"},{"key":"e_1_2_11_6_2","volume-title":"Infectious Diseases Society of America Antimicrobial-Resistant Treatment Guidance: Gram-Negative Bacterial Infections","author":"Tamma P. D.","year":"2023"},{"key":"e_1_2_11_7_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.1045206"},{"key":"e_1_2_11_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12363"},{"key":"e_1_2_11_9_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.709974"},{"key":"e_1_2_11_10_2","unstructured":"Sulbactam\u2010Durlobactam for Injection Applicant: Entasis Therapeutics Inc. Antimicrobial Drugs Advisory Committee Meeting 04\/17\/23 Division of Anti\u2010Infectives\/Office of Infectious Diseases 2023 FDA Briefing Document NDA 216974 Drug Name"},{"key":"e_1_2_11_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2013.07.012"},{"key":"e_1_2_11_12_2","doi-asserted-by":"publisher","DOI":"10.2147\/idr.s332160"},{"key":"e_1_2_11_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt275"},{"key":"e_1_2_11_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/nmicrobiol.2017.104"},{"key":"e_1_2_11_15_2","unstructured":"2024 https:\/\/www.rxlist.com\/xacduro-drug.htm."},{"key":"e_1_2_11_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11908-019-0706-5"},{"key":"e_1_2_11_17_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200767130-00003"},{"key":"e_1_2_11_18_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10111344"},{"key":"e_1_2_11_19_2","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.814530"},{"key":"e_1_2_11_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00781-22"},{"key":"e_1_2_11_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa119"},{"key":"e_1_2_11_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa208"},{"key":"e_1_2_11_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01698-23"},{"key":"e_1_2_11_24_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics9040205"},{"key":"e_1_2_11_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01576-17"},{"key":"e_1_2_11_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00794-19"},{"key":"e_1_2_11_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01506-19"},{"key":"e_1_2_11_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01089-18"},{"key":"e_1_2_11_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2014.02.012"},{"key":"e_1_2_11_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad096"},{"key":"e_1_2_11_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.00159-19"},{"key":"e_1_2_11_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(23)00184-6"},{"key":"e_1_2_11_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00071-20"},{"key":"e_1_2_11_34_2","article-title":"Prescribing Information","author":"Xacduro","year":"2023","journal-title":"Entasis Therapeutics Ltd"},{"key":"e_1_2_11_35_2","volume-title":"Presentation Presented at: ID Week 2022","author":"Carter N. M.","year":"2022"},{"key":"e_1_2_11_36_2","unstructured":"Imipenem-Relebactam Red Book Online. Micromedex Healthcare Series 2023."},{"key":"e_1_2_11_37_2","unstructured":"RxNorm October 2023 Monthly Release NLM Technical Bulletin."},{"key":"e_1_2_11_38_2","unstructured":"Ceftazidime-avibactam Red Book Online. Micromedex Healthcare Series 2023."},{"key":"e_1_2_11_39_2","unstructured":"Sulbactam-durlobactam Red Book Online. Micromedex Healthcare Series 2023."},{"key":"e_1_2_11_40_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00924-21"},{"key":"e_1_2_11_41_2","article-title":"Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections","author":"Tamma P. D.","journal-title":"Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America"}],"container-title":["Canadian Journal of Infectious Diseases and Medical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/cjid\/2001136","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1155\/cjid\/2001136","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/cjid\/2001136","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T22:25:04Z","timestamp":1773008704000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1155\/cjid\/2001136"}},"subtitle":[],"editor":[{"given":"Vijay","family":"Gondil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1155\/cjid\/2001136"],"URL":"https:\/\/doi.org\/10.1155\/cjid\/2001136","archive":["Portico"],"relation":{},"ISSN":["1712-9532","1918-1493"],"issn-type":[{"value":"1712-9532","type":"print"},{"value":"1918-1493","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"2024-07-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2001136"}}